CureVac/$CVAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CureVac
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Ticker
$CVAC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
904
ISIN
NL0015436031
Website
CureVac Metrics
BasicAdvanced
$1B
5.09
$0.91
2.43
-
Price and volume
Market cap
$1B
Beta
2.43
52-week high
$5.28
52-week low
$2.37
Average daily volume
668K
Financial strength
Current ratio
7.654
Quick ratio
7.327
Long term debt to equity
4.976
Total debt to equity
5.78
Management effectiveness
Return on assets (TTM)
19.93%
Return on equity (TTM)
33.04%
Valuation
Price to earnings (TTM)
5.091
Price to revenue (TTM)
1.75
Price to book
1.61
Price to tangible book (TTM)
1.68
Price to free cash flow (TTM)
6.402
Growth
Revenue change (TTM)
787.60%
Earnings per share change (TTM)
-165.62%
3-year revenue growth (CAGR)
64.65%
3-year earnings per share growth (CAGR)
-21.81%
What the Analysts think about CureVac
Analyst ratings (Buy, Hold, Sell) for CureVac stock.
CureVac Financial Performance
Revenues and expenses
CureVac Earnings Performance
Company profitability
CureVac News
AllArticlesVideos
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
Accesswire·1 week ago
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
Accesswire·2 weeks ago
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CureVac stock?
CureVac (CVAC) has a market cap of $1B as of May 30, 2025.
What is the P/E ratio for CureVac stock?
The price to earnings (P/E) ratio for CureVac (CVAC) stock is 5.09 as of May 30, 2025.
Does CureVac stock pay dividends?
No, CureVac (CVAC) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next CureVac dividend payment date?
CureVac (CVAC) stock does not pay dividends to its shareholders.
What is the beta indicator for CureVac?
CureVac (CVAC) has a beta rating of 2.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.